1Gupta S, Mosnik D, Black DW, Berry S, Masand PS. Tardive dyskinesia: review of treatments past, present, and future. Ann Clin Psychiatry. 1999;11:257-266.
2Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull. 1997;23:583-609.
3Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris MJ, Caligiuri MP. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry. 1999;156:309-311.
4Woerner MG, Alvir JMJ, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998;155:1521-1528.
5Coulter DM, Pillans PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry. 1995;152:122-125.
6Bonin B, Vandel P, Sechter D, Bizouard P. Paroxetine and galactorrhea. Pharmacopsychiatry. 1997;30:133-134.
7Diler RS, Yolga A, Avci A. Fluoxetine-induced extrapyramidal symptoms in an adolescent: a case report. Swiss mMed Week. 2002;132:125-126.
8Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996;57:449-454.
9Fernandez HH, Friedman JH. Classification and treatment of tardive syndromes. The nNeurologist. 2003;9:16-27.
10Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21:151-156.
11Weiner WJ, Lang AE. Movement Disorders: A Comprehensive Survey - Hardcover. 1989.
12Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry. 2005;50:541-547.
13Demirkol ME, Şenbayram Ş, Doğangüneş G, Tamam L. Tardif diskinezi ve tedavi yaklaşımları. Psikiyatride Güncel Yaklaşımlar. 2018;10:249-264.
14Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol1997;17:377-389.
15Caley CF. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother1997;31:1481-1489.
16Schillevoort I, Van Puijenbroek E, de Boer A, Roos R, Jansen PA, Leufkens H. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. IntClin Psychopharmacol. 2002;17:75-79.
17Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153:466-476.
18DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry. 1994;55:38-45.
19DeVane CL. Pharmacokinetics of the newer antidepressants: clinical relevance. Am JMed. 1994;97:13-23.
20Steur EN. Increase of Parkinson disability after fluoxetine medication. Neurology. 1993;43:211-213.